Robeco Institutional Asset Management B.V. Has $176.04 Million Position in Baxter International Inc (BAX)

Robeco Institutional Asset Management B.V. lessened its holdings in Baxter International Inc (NYSE:BAX) by 1.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,283,099 shares of the medical instruments supplier’s stock after selling 37,596 shares during the period. Baxter International comprises 0.7% of Robeco Institutional Asset Management B.V.’s investment portfolio, making the stock its 22nd biggest holding. Robeco Institutional Asset Management B.V. owned 0.43% of Baxter International worth $176,038,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of BAX. FMR LLC grew its position in shares of Baxter International by 25.6% during the 2nd quarter. FMR LLC now owns 28,637,027 shares of the medical instruments supplier’s stock valued at $2,114,558,000 after acquiring an additional 5,845,720 shares during the period. Voya Investment Management LLC grew its position in shares of Baxter International by 411.6% during the 2nd quarter. Voya Investment Management LLC now owns 3,411,849 shares of the medical instruments supplier’s stock valued at $251,931,000 after acquiring an additional 2,745,012 shares during the period. Morgan Stanley grew its position in shares of Baxter International by 107.8% during the 2nd quarter. Morgan Stanley now owns 2,873,253 shares of the medical instruments supplier’s stock valued at $212,161,000 after acquiring an additional 1,490,287 shares during the period. Standard Life Aberdeen plc grew its position in shares of Baxter International by 77.2% during the 2nd quarter. Standard Life Aberdeen plc now owns 2,596,870 shares of the medical instruments supplier’s stock valued at $191,753,000 after acquiring an additional 1,131,691 shares during the period. Finally, Swiss National Bank grew its position in shares of Baxter International by 6.1% during the 2nd quarter. Swiss National Bank now owns 2,191,439 shares of the medical instruments supplier’s stock valued at $161,816,000 after acquiring an additional 125,700 shares during the period. Institutional investors own 82.28% of the company’s stock.

BAX opened at $63.48 on Friday. The company has a market capitalization of $33.79 billion, a P/E ratio of 25.60, a price-to-earnings-growth ratio of 1.71 and a beta of 1.02. Baxter International Inc has a 12 month low of $61.05 and a 12 month high of $78.38. The company has a quick ratio of 2.00, a current ratio of 2.60 and a debt-to-equity ratio of 0.38.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Wednesday, October 31st. The medical instruments supplier reported $0.80 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.06. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.79 billion. Baxter International had a net margin of 10.90% and a return on equity of 17.67%. Baxter International’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period last year, the firm earned $0.64 EPS. On average, equities analysts expect that Baxter International Inc will post 3 earnings per share for the current year.

In related news, SVP Giuseppe Accogli sold 17,647 shares of the firm’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $77.27, for a total value of $1,363,583.69. Following the completion of the transaction, the senior vice president now directly owns 59,452 shares of the company’s stock, valued at approximately $4,593,856.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.05% of the stock is currently owned by company insiders.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 target price for the company in a research report on Tuesday, September 25th. Argus reissued a “hold” rating on shares of Baxter International in a research report on Tuesday, September 4th. JPMorgan Chase & Co. increased their target price on shares of Baxter International from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday, July 27th. Royal Bank of Canada reissued a “hold” rating and set a $76.00 target price on shares of Baxter International in a research report on Friday, July 27th. Finally, Piper Jaffray Companies raised their price objective on shares of Baxter International from $77.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, July 27th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the stock. Baxter International presently has a consensus rating of “Buy” and an average price target of $75.25.

WARNING: “Robeco Institutional Asset Management B.V. Has $176.04 Million Position in Baxter International Inc (BAX)” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/11/10/robeco-institutional-asset-management-b-v-has-176-04-million-position-in-baxter-international-inc-bax.html.

Baxter International Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: Find a Trading Strategy That Works

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply